Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Burney Co.

Burney Co. lowered its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 50.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,503 shares of the company's stock after selling 13,849 shares during the quarter. Burney Co.'s holdings in Neurocrine Biosciences were worth $1,493,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NBIX. Envestnet Portfolio Solutions Inc. raised its holdings in Neurocrine Biosciences by 10.7% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,868 shares of the company's stock worth $391,000 after purchasing an additional 278 shares in the last quarter. Corient Private Wealth LLC raised its holdings in Neurocrine Biosciences by 64.0% during the fourth quarter. Corient Private Wealth LLC now owns 7,927 shares of the company's stock worth $1,082,000 after purchasing an additional 3,094 shares in the last quarter. LPL Financial LLC raised its holdings in Neurocrine Biosciences by 27.8% during the fourth quarter. LPL Financial LLC now owns 16,754 shares of the company's stock worth $2,287,000 after purchasing an additional 3,643 shares in the last quarter. Vanguard Group Inc. raised its holdings in Neurocrine Biosciences by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 10,119,641 shares of the company's stock worth $1,381,331,000 after purchasing an additional 122,681 shares in the last quarter. Finally, Segall Bryant & Hamill LLC raised its holdings in Neurocrine Biosciences by 28.5% during the fourth quarter. Segall Bryant & Hamill LLC now owns 46,870 shares of the company's stock worth $6,398,000 after purchasing an additional 10,398 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company's stock.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Jude Onyia sold 59,819 shares of the firm's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $130.46, for a total transaction of $7,803,986.74. Following the sale, the insider directly owned 18,289 shares of the company's stock, valued at $2,385,982.94. This trade represents a 76.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ingrid Delaet sold 457 shares of the firm's stock in a transaction dated Thursday, July 10th. The stock was sold at an average price of $135.00, for a total transaction of $61,695.00. Following the sale, the insider directly owned 4,730 shares in the company, valued at $638,550. This represents a 8.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 120,251 shares of company stock valued at $14,978,602 over the last 90 days. 4.80% of the stock is currently owned by corporate insiders.

Neurocrine Biosciences Trading Up 0.4%

Shares of NASDAQ:NBIX traded up $0.50 on Friday, reaching $132.14. 1,255,339 shares of the company were exchanged, compared to its average volume of 752,857. Neurocrine Biosciences, Inc. has a 1-year low of $84.23 and a 1-year high of $157.98. The firm has a market cap of $13.08 billion, a price-to-earnings ratio of 44.79, a price-to-earnings-growth ratio of 1.35 and a beta of 0.24. The company has a 50-day moving average of $126.91 and a 200-day moving average of $121.34.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.08 earnings per share for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). Neurocrine Biosciences had a return on equity of 11.81% and a net margin of 12.68%. The company had revenue of $572.60 million for the quarter, compared to analyst estimates of $587.06 million. During the same period last year, the company earned $1.20 earnings per share. The business's revenue for the quarter was up 11.1% compared to the same quarter last year. As a group, analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on NBIX. Evercore ISI cut their price objective on shares of Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. The Goldman Sachs Group initiated coverage on shares of Neurocrine Biosciences in a report on Thursday, July 10th. They issued a "buy" rating and a $182.00 target price on the stock. Wedbush reiterated an "outperform" rating on shares of Neurocrine Biosciences in a research report on Tuesday, May 6th. HC Wainwright reduced their price target on shares of Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating for the company in a research report on Tuesday, April 22nd. Finally, Guggenheim upped their price target on shares of Neurocrine Biosciences from $155.00 to $165.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Three equities research analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the company. According to MarketBeat, Neurocrine Biosciences presently has a consensus rating of "Moderate Buy" and an average price target of $163.87.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.